What the trial was testing
The MYCARING enrolled 71 patients with myasthenia gravis. The study was sponsored by UCB Biopharma SRL and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
Patients had a 3.4-point improvement in daily living scores versus 0.8 with placebo.
The Lancet. Neurology · 2023 · NCT04124965
These findings — that weekly rozanolixizumab reduced myasthenia gravis symptoms much more than placebo — were published in the The Lancet. Neurology and represent the headline result of the study.
Researchers tracked outcomes across 71 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with myasthenia gravis, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Rozanolixizumab was approved by the FDA in 2023 for adults with myasthenia gravis. It's given as a weekly injection under the skin for 6 weeks. Talk to your neurologist to see if this treatment is right for you, especially if current therapies aren't controlling your symptoms well enough.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open myasthenia gravis trials
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
This is a phase I/II study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis. YTB323 is a Biological CAR-T cell therapy.
Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia
This is a multicenter, non-interventional, retrospective-prospective, single-arm observational study designed to describe real-world treatment approaches and clinical outcomes among adults with acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) in routine clinical practice in Russia.